Volume 21, Number 3—March 2015
Research
Mycoplasma pneumoniae and Chlamydia spp. Infection in Community-Acquired Pneumonia, Germany, 2011–2012
Table 1
Demographic and clinical characteristics of patients with community-acquired pneumonia whose respiratory tract samples were tested for Mycoplasma pneumoniae, Germany, 2011–2012*
Characteristic | All, n = 783 | M. pneumoniae–positive, n = 96 | M. pneumoniae–negative, n = 687 | p value† |
---|---|---|---|---|
Median age, y (range) | 61 (18–102) | 39.5 (18–84) | 64 (18–102) | <0.001 |
Male sex | 56.8 | 43.8 | 58.7 | 0.008 |
BMI (range) |
25.6 (13.9–56.5) |
24.2 (18.8–44.5) |
25.8 (13.9–56.5) |
|
Co-occurring conditions | ||||
Chronic pulmonary disease | 19.2 | 6.2 | 23.1 | <0.001 |
Chronic renal disease | 19.2 | 0 | 20.6 | 0.004 |
Chronic heart failure | 26.1 | 11.3 | 27.2 | |
Diabetes mellitus | 24.9 | 11.1 | 25.9 | |
Cerebro-vascular disease |
9.5 |
3.7 |
9.3 |
|
CURB scores‡ | <0.001 | |||
0 | 57.3 | 77.0 | 54.7 | |
1 | 31.0 | 21.8 | 32.2 | |
2 | 10.5 | 1.1 | 11.8 | |
3 | 1.2 | 0 | 1.4 | |
4 |
0 |
0 |
0 |
|
Antimicrobial drug pretreatment | 29.3 | 51.0 | 26.2 | <0.001 |
Macrolides |
8.0 |
7.3 |
8.3 |
§ |
Mortality rate | ||||
28 d | 1.8 | 0 | 2.0 | |
180 d | 4.6 | 0 | 5.2 |
*Values are percentages except as indicated. BMI, body mass index.
†Only significant values are shown. Comparison between M. pneumoniae-positive and -negative patients by χ2 or Mann-Whitney U test as appropriate.
‡Clinical evaluation of the following risk factors (each scores 1 point): Confusion; blood Urea >7 mmol/L; Respiratory rate ≥30 bpm; Blood pressure <90 (systolic) or ≤60 mm Hg (diastolic).
§Also no significant differences for any other antimicrobial drug classes.
1Joint senior authors.
2Members of the CAPNETZ Study Group are listed at the end of this article.
Page created: February 18, 2015
Page updated: February 18, 2015
Page reviewed: February 18, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.